fda glp-1 warning news november 2025 Pipeline Update: August - Prime Therapeutics GLP-1 Weight-Loss Drug Demonstration Begins

Of course it's going to modify things like compulsive behavior and addictive behavior." The evidence: JAMA Psychiatry published a paper in February showing semaglutide significantly reduced drinking episodes in alcohol use disorder

Participants with obesity (body mass index (BMI) 30 kg/m) and moderate-to-severe KOA pain experienced significantly greater reductions in body weight and OA-related pain with weekly semaglutide injections compared to placebo [52]

Other drugs designed to help reduce alcohol intake act upon the nervous system, researchers noted

10.2337/dc14-0514 [DOI] [PubMed] [Google Scholar] 92.Kiesewetter DO, Gao H, Ma Y, Niu G, Quan Q, Guo N, et al

Assessment HOMA as a predictor for new onset diabetes mellitus and diabetic complications in non-diabetic adults: a KoGES prospective cohort study